Puma Biotechnology Inc. (PBYI)’s Financial Results Comparing With Coherus BioSciences Inc. (NASDAQ:CHRS)

As Biotechnology companies, Puma Biotechnology Inc. (NASDAQ:PBYI) and Coherus BioSciences Inc. (NASDAQ:CHRS) are our subject to contrast. And more specifically their analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Puma Biotechnology Inc. 201.52M 5.11 146.96M -3.90 0.00
Coherus BioSciences Inc. N/A 0.00 195.81M -3.13 0.00

Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 shows us the return on assets, net margins and return on equity of both companies.

Net Margins Return on Equity Return on Assets
Puma Biotechnology Inc. -72.93% -301.5% -74.1%
Coherus BioSciences Inc. 0.00% -741.7% -126.2%

Volatility and Risk

Puma Biotechnology Inc. has a beta of -0.13 and its 113.00% less volatile than Standard and Poor’s 500. Competitively, Coherus BioSciences Inc.’s beta is 3.65 which is 265.00% more volatile than Standard and Poor’s 500.

Liquidity

The Current Ratio and a Quick Ratio of Puma Biotechnology Inc. are 3 and 3. Competitively, Coherus BioSciences Inc. has 5.3 and 5.3 for Current and Quick Ratio. Coherus BioSciences Inc.’s better ability to pay short and long-term obligations than Puma Biotechnology Inc.

Analyst Recommendations

In next table is given Puma Biotechnology Inc. and Coherus BioSciences Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Puma Biotechnology Inc. 0 0 0 0.00
Coherus BioSciences Inc. 0 0 1 3.00

On the other hand, Coherus BioSciences Inc.’s potential upside is 103.64% and its consensus target price is $28.

Institutional and Insider Ownership

The shares of both Puma Biotechnology Inc. and Coherus BioSciences Inc. are owned by institutional investors at 95.8% and 95.7% respectively. Insiders owned roughly 11.3% of Puma Biotechnology Inc.’s shares. Competitively, Coherus BioSciences Inc. has 0.1% of it’s share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Puma Biotechnology Inc. 3.83% 4.59% -49.57% -50.45% -77.02% -75.59%
Coherus BioSciences Inc. -10.04% -20.27% -44.41% -37.81% 17.75% 13.07%

For the past year Puma Biotechnology Inc. has -75.59% weaker performance while Coherus BioSciences Inc. has 13.07% stronger performance.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care. Its drug candidates include PB272 (neratinib (oral)) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 (neratinib (intravenous)). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company’s product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non–small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behçet's Disease, Crohn’s Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; Genentech, Inc.; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.